These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27751896)

  • 1. Non-Vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation: An Updated Meta-analysis.
    Renda G; Ricci F; De Caterina R
    Am J Med; 2017 Apr; 130(4):457-461. PubMed ID: 27751896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
    Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
    Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis.
    Brunetti ND; Tarantino N; De Gennaro L; Correale M; Santoro F; Di Biase M
    J Thromb Thrombolysis; 2018 May; 45(4):550-556. PubMed ID: 29404874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
    Flaker G; Lopes RD; Al-Khatib SM; Hermosillo AG; Hohnloser SH; Tinga B; Zhu J; Mohan P; Garcia D; Bartunek J; Vinereanu D; Husted S; Harjola VP; Rosenqvist M; Alexander JH; Granger CB;
    J Am Coll Cardiol; 2014 Mar; 63(11):1082-7. PubMed ID: 24211508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis.
    Telles-Garcia N; Dahal K; Kocherla C; Lip GYH; Reddy P; Dominic P
    Int J Cardiol; 2018 Oct; 268():143-148. PubMed ID: 30041779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes After Cardioversion in Atrial Fibrillation Patients Treated with Non-Vitamin K Antagonist Oral Anticoagulants (NOACs): Insights from a Meta-Analysis.
    Sen P; Kundu A; Sardar P; Chatterjee S; Nairooz R; Amin H; Aronow WS
    Am J Cardiovasc Drugs; 2016 Feb; 16(1):33-41. PubMed ID: 26138204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New oral anticoagulants versus vitamin K antagonists before cardioversion of atrial fibrillation: a meta-analysis of data from 4 randomized trials.
    Andò G; Trio O; Carerj S
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):577-83. PubMed ID: 25797595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin.
    Frederiksen AS; Albertsen AE; Christesen AMS; Vinter N; Frost L; Møller DS
    Europace; 2018 Jul; 20(7):1078-1085. PubMed ID: 28655151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients Undergoing Cardioversion for Atrial Fibrillation: a Systematic Review and Meta-analysis.
    Gupta S; Um KJ; Pandey A; McIntyre WF; Ivanova M; Allahverdi Y; Agahi P; Pandya F; Lopez A; Sachdeva A; Whitlock RP; Belley-Cote EP
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):339-352. PubMed ID: 31011880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of direct oral anticoagulants versus vitamin K antagonists in atrial fibrillation electrical cardioversion: An update systematic review and meta-analysis.
    Troisi F; Guida P; Vitulano N; Quadrini F; Di Monaco A; Grimaldi M
    Int J Cardiol; 2023 May; 379():40-47. PubMed ID: 36907451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion.
    Itäinen S; Lehto M; Vasankari T; Mustonen P; Kotamäki M; Numminen A; Lahtela H; Bah A; Hartikainen J; Hekkala AM; Airaksinen JKE
    Europace; 2018 Apr; 20(4):565-568. PubMed ID: 29016758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.
    Nairooz R; Sardar P; Pino M; Aronow WS; Sewani A; Mukherjee D; Paydak H; Maskoun W
    Int J Cardiol; 2015; 187():345-53. PubMed ID: 25839640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Deng Y; Tong Y; Deng Y; Zou L; Li S; Chen H
    J Am Heart Assoc; 2019 Jul; 8(14):e012540. PubMed ID: 31310583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard dose versus low dose non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of contemporary randomized controlled trials.
    Wang KL; Giugliano RP; Goto S; Chiu CC; Lin CY; Lai EY; Chiang CE
    Heart Rhythm; 2016 Dec; 13(12):2340-2347. PubMed ID: 27614026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.
    Carnicelli AP; Hong H; Connolly SJ; Eikelboom J; Giugliano RP; Morrow DA; Patel MR; Wallentin L; Alexander JH; Cecilia Bahit M; Benz AP; Bohula EA; Chao TF; Dyal L; Ezekowitz M; A A Fox K; Gencer B; Halperin JL; Hijazi Z; Hohnloser SH; Hua K; Hylek E; Toda Kato E; Kuder J; Lopes RD; Mahaffey KW; Oldgren J; Piccini JP; Ruff CT; Steffel J; Wojdyla D; Granger CB;
    Circulation; 2022 Jan; 145(4):242-255. PubMed ID: 34985309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis.
    Santarpia G; De Rosa S; Polimeni A; Giampà S; Micieli M; Curcio A; Indolfi C
    PLoS One; 2015; 10(5):e0126512. PubMed ID: 25974377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials.
    Kwong JS; Lam YY; Yan BP; Yu CM
    Cardiovasc Drugs Ther; 2013 Feb; 27(1):23-35. PubMed ID: 23224686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
    Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.